Get the Stockscreener App
0.589
1.95%
-0.0117
After Hours:
.57
-0.019
-3.23%
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Matinas Biopharma Announces Agreement For The Acquisition Of Preferred Stock And Appointment Of Dr. Robin L. Smith To The Board Of Directors - Marketscreener.com
Matinas BioPharma Announces Agreement for the Acquisition - GlobeNewswire
Biotech Deal Alert: Matinas BioPharma Lands Critical $3.3M Investment While Strengthening Leadership - StockTitan
Matinas BioPharma announces board member retirement - MSN
Matinas BioPharma announces board member retirement By Investing.com - Investing.com South Africa
Matinas BioPharma Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Matinas Biopharma Appoints Evelyn D’An as Director and Audit Committee Chair - Armenian Reporter
Matinas BioPharma Appoints Evelyn D’An to Board - citybiz
Matinas BioPharma Holdings, Inc. Appoints Evelyn D?An to Board of Directors as an Independent Director and Chair of the Audit Committee - Marketscreener.com
Matinas Biopharma Appoints Evelyn D'An To Board Of Directors As Audit Committee Chair - Marketscreener.com
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair - The Manila Times
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair - GlobeNewswire
Matinas BioPharma announces board member resignation - MSN
Matinas BioPharma announces board member resignation By Investing.com - Investing.com South Africa
Matinas Biopharma Holdings, Inc. Announces Resignation of James S. Scibetta from Board and Audit and Compensation Committees - Marketscreener.com
111 Equity Group Increases Stake In Matinas Biopharma Holdings - citybiz
111 Equity ups stake in Matinas Biopharma Holdings - Investing.com
Activist Investor 111 Equity Takes 5.17% Stake in Matinas BioPharma, Seeks Value Creation - StockTitan
**Matinas BioPharma Receives Notice of Noncompliance from NYSE American** - Defense World
Matinas BioPharma Receives NYSE Noncompliance Notice - GlobeNewswire
Matinas BioPharma Receives NYSE American Noncompliance Notice Over Delayed Annual Meeting - StockTitan
State Street Corp Has $54,000 Stock Position in Matinas Biopharma Holdings, Inc. (NYSE:MTNB) - Defense World
MTNB stock touches 52-week low at $0.5 amid sharp annual decline - Investing.com
Matinas Biopharma (NYSE:MTNB) Shares Down 1.3% – What’s Next? - Defense World
Matinas Biopharma Holdings, Inc. Announces Resignation of Kathryn Penkus Corzo from Board, Compensation and Nominating and Corporate Governance Committees - Marketscreener.com
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MTNB (Matinas BioPharma Holdings) EPS (Diluted) : $-4.79 (TTM As of Sep. 2024) - GuruFocus.com
Maxim Group Reiterates Hold Rating for Matinas BioPharma (NYSEAMERICAN:MTNB) - Defense World
MTNBMatinas BioPharma Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Matinas BioPharma plunges as deal for lead asset falls apart - MSN
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through - Pharmaceutical Technology
Matinas BioPharma stock falls on strategic options (MTNB:NYSE) - Seeking Alpha
Nasdaq Down Over 200 Points; Microsoft Shares Fall After Q1 Results - Benzinga
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction - The Manila Times
Matinas BioPharma Announces the Termination of MAT2203 - GlobeNewswire
Crude Oil Gains 1%; Meta Shares Fall Following Q3 Results - Benzinga
MTNB stock touches 52-week low at $2.87 amid market challenges - Investing.com Canada
Richmond pharma firm Kaléo appoints new chief development officer - The Business Journals
MTNB stock touches 52-week low at $2.87 amid market challenges By Investing.com - Investing.com South Africa
Highbridge Capital Management's Strategic Acquisition in Matinas BioPharma - GuruFocus.com
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):